Angiogenesis is a critical process in the development and progression of meningioma

Oct 13, 2025 by magicalceylontours.com 43 views

Relationship of Fibroblast Growth Factor-2 (FGF-2) and Vascular Endothelial Growth Factor (VEGF) Expression with Grade Histopathology Meningioma

Meningioma is a type of intracranial primary tumor that is often found, with an incident reaching 36% of all tumors in the central nervous system in the United States. The growth of solid tumors such as meningioma is very dependent on the angiogenesis process, namely the formation of new blood vessels that support the supply of nutrients and oxygen to tumor cells. Vascular Endothelial Growth Factor (VEGF) and Fibroblast growth factor-2 (FGF-2) are two angiogenic factors that play a crucial role in the arrangement of angiogenesis. Although previous research has examined these two factors using blood serum samples, this research is different because it uses the immunohistochemical method carried out in tumor tissue.

Research Background

Meningioma is a type of tumor that originates from the meninges, the protective membranes surrounding the brain and spinal cord. It is a common type of brain tumor, accounting for about 36% of all primary brain tumors in the United States. The growth of meningioma is influenced by various factors, including angiogenesis, which is the formation of new blood vessels that supply nutrients and oxygen to the tumor cells. Angiogenesis is a critical process in the development and progression of meningioma.

Research Purposes

This study aims to evaluate the relationship between FGF-2 and VEGF immunohistochemical expression with various histopathology grade in meningioma patients. By understanding this connection, it is expected that the potential for prognostic indicators to assess tumor aggressiveness and more effective therapy strategies. The evaluation of FGF-2 and VEGF expression can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis.

Research Methods

In this cross-sectional study, 32 meningioma patients were taken to be fixed tissue blocks in formalin and then analyzed for FGF-2 and VEGF expressions using the immunohistochemical method. Each case of meningioma is diagnosed based on subtype and grade histopathology. The data obtained were analyzed statistically using the Mann-Whitney, Kruskal-Wallis, and Dunn tests to determine the relationship between VEGF and FGF-2 expressions with histopathology grade.

Research Result

The results show that there is a significant difference between FGF-2 and VEGF expressions with meningioma histopathology grade (p <0.05). Most negative cases for FGF-2 are found in grade meningiomas 1 (91.6%), while 50% of grade 2 meningioma indicates a positive FGF-2 expression. For VEGF's expression, although the majority of VEGF values are in grade 1 meningioma, all cases of grade 3 meningiomas show high VEGF expressions. These findings highlight the importance of FGF-2 and VEGF in the angiogenesis process that occurs in meningiomas, especially in tumors with higher histopathological grade.

Additional Analysis and Explanation

Increased VEGF and FGF-2 expression can be an indicator that the tumor is more aggressive and has the potential to experience faster growth. Therefore, the evaluation of the level of expression of these two factors can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis. The positive expressions of FGF-2 and Vegf high in meningiomas that have a higher grade indicate that angiogenesis has a crucial role in tumor growth, especially in more ferocious cases.

Conclusion

The results of this study can be used as a prognostic indicator as well as a target in developing therapy for neoplasm meningioma, which in turn can increase the clinical outcome of the patient. Further research is still needed to explore the molecular mechanisms that underlie this relationship and the potential for its application in clinical practice. The evaluation of FGF-2 and VEGF expression can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis.

Future Research Directions

Further research is needed to explore the molecular mechanisms that underlie the relationship between FGF-2 and VEGF expression with meningioma histopathology grade. This includes investigating the role of other angiogenic factors and the potential for their application in clinical practice. Additionally, the development of targeted therapies that inhibit the expression of FGF-2 and VEGF may provide a new approach to treating meningioma.

Clinical Implications

The evaluation of FGF-2 and VEGF expression can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis. This can lead to improved clinical outcomes for patients with meningioma. Additionally, the development of targeted therapies that inhibit the expression of FGF-2 and VEGF may provide a new approach to treating meningioma.

Limitations of the Study

This study has several limitations. The sample size was relatively small, and the study was conducted in a single institution. Additionally, the study only evaluated the expression of FGF-2 and VEGF, and did not investigate the role of other angiogenic factors. Further research is needed to confirm the findings of this study and to explore the molecular mechanisms that underlie the relationship between FGF-2 and VEGF expression with meningioma histopathology grade.

Conclusion

In conclusion, this study highlights the importance of FGF-2 and VEGF in the angiogenesis process that occurs in meningiomas, especially in tumors with higher histopathological grade. The evaluation of FGF-2 and VEGF expression can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis. Further research is still needed to explore the molecular mechanisms that underlie this relationship and the potential for its application in clinical practice.
Frequently Asked Questions (FAQs) about the Relationship between Fibroblast Growth Factor-2 (FGF-2) and Vascular Endothelial Growth Factor (VEGF) Expression with Grade Histopathology Meningioma

Q: What is meningioma?

A: Meningioma is a type of intracranial primary tumor that is often found, with an incident reaching 36% of all tumors in the central nervous system in the United States.

Q: What is angiogenesis?

A: Angiogenesis is the formation of new blood vessels that supply nutrients and oxygen to the tumor cells. It is a critical process in the development and progression of meningioma.

Q: What are FGF-2 and VEGF?

A: FGF-2 and VEGF are two angiogenic factors that play a crucial role in the arrangement of angiogenesis. They are involved in the formation of new blood vessels that supply nutrients and oxygen to the tumor cells.

Q: What is the relationship between FGF-2 and VEGF expression with meningioma histopathology grade?

A: The results of this study show that there is a significant difference between FGF-2 and VEGF expressions with meningioma histopathology grade. Most negative cases for FGF-2 are found in grade meningiomas 1 (91.6%), while 50% of grade 2 meningioma indicates a positive FGF-2 expression. For VEGF's expression, although the majority of VEGF values are in grade 1 meningioma, all cases of grade 3 meningiomas show high VEGF expressions.

Q: What are the implications of this study?

A: The evaluation of FGF-2 and VEGF expression can help doctors in planning therapy that are more targeted and estimate the possibility of patient prognosis. This can lead to improved clinical outcomes for patients with meningioma.

Q: What are the limitations of this study?

A: This study has several limitations. The sample size was relatively small, and the study was conducted in a single institution. Additionally, the study only evaluated the expression of FGF-2 and VEGF, and did not investigate the role of other angiogenic factors.

Q: What are the future research directions?

A: Further research is needed to explore the molecular mechanisms that underlie the relationship between FGF-2 and VEGF expression with meningioma histopathology grade. This includes investigating the role of other angiogenic factors and the potential for their application in clinical practice.

Q: What are the clinical implications of this study?

Q: What are the potential applications of this study?

A: The findings of this study can be used as a prognostic indicator as well as a target in developing therapy for neoplasm meningioma, which in turn can increase the clinical outcome of the patient.

Q: What are the potential risks associated with this study?

A: There are no potential risks associated with this study, as it is a retrospective study that only analyzed existing data.

Q: What are the potential benefits of this study?

A: The potential benefits of this study include improved clinical outcomes for patients with meningioma, as well as the development of targeted therapies that inhibit the expression of FGF-2 and VEGF.

Q: What are the next steps in this research?

A: Further research is needed to confirm the findings of this study and to explore the molecular mechanisms that underlie the relationship between FGF-2 and VEGF expression with meningioma histopathology grade. This includes investigating the role of other angiogenic factors and the potential for their application in clinical practice.